logo
logo
Senseonics Holdings, Inc.

Senseonics Holdings, Inc.

AMEX•SENS
CEO: Dr. Timothy T. Goodnow Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2015-12-22
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
連絡先情報
20451 Seneca Meadows Parkway, Germantown, MD, 20876-7005, United States
301-515-7260
www.senseonics.com
時価総額
$338.31M
PER (TTM)
-5.7
3.6
配当利回り
--
52週高値
$28.00
52週安値
$5.25
52週レンジ
13%
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$8.10M+89.89%
直近4四半期の推移

EPS

-$0.43-44.30%
直近4四半期の推移

フリーCF

-$15.98M+9.37%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Nine Months Total revenue increased $6.83M to $21.00M for nine months ended September 2025, driven by consignment growth.
Gross Profit Turnaround Gross profit improved $11.51M to $8.09M profit for nine months ended September 2025, benefiting from prior year charges.
Equity Position Swing Stockholders' equity swung $94.72M to $78.17M positive balance as of September 30, 2025, reversing deficit.
Financing Provided Cash $77.09M cash provided by financing activities for nine months 2025, largely from recent Public Offering proceeds.

リスク要因

Going Concern Substantial Doubt Substantial doubt exists regarding ability to continue as going concern past twelve months without additional liquidity.
Ascensia Transition Uncertainty Commercial transition from Ascensia starting 2026 involves uncertain final terms, costs, and liabilities negotiation.
Liquidity Needs Critical Requires additional capital funding over next twelve months to sustain operations and expanded commercialization efforts.
Limited Commercial Experience Limited commercial stage history facing difficulties in competitive, rapidly evolving medical device markets.

見通し

Resume US Commercial Control Plan to resume US commercial responsibility from Ascensia starting January 1, 2026, pending definitive agreement.
New Product Development Focus Advancing Gemini product development; seeking IDE submission by end of 2025 based on 365-day sensor data.
Sequel Collaboration Integration Integrating Sequel Med Tech technologies to create first automated insulin delivery system by Q4 2025.
Evaluate Funding Strategies Evaluating strategies to obtain required additional funding through public or private debt and equity financings.

同業比較

売上高 (TTM)

Owens & Minor, Inc.OMI
$6.71B
+44.5%
The Oncology Institute, Inc.TOI
$461.04M
+21.7%
Treace Medical Concepts, Inc.TMCI
$218.88M
+7.9%

粗利益率 (最新四半期)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
CVRx, Inc.CVRX
86.8%
+3.6pp
Sight Sciences, Inc.SGHT
86.4%
+2.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CAPR$1.13B-13.7-71.0%11.5%
SRDX$614.51M-34.8-15.6%19.2%
NPCE$508.94M-21.1-136.6%66.4%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.8%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月2日
|
EPS:-$0.43
|
売上高:$14.20M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $8.10M+89.9%
    |
    EPS: $-0.43-44.3%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $8.30M+70.5%
    |
    EPS: $-0.52-21.0%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $6.26M+24.0%
    |
    EPS: $-0.40-35.5%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|
    売上高: $22.47M+0.4%
    |
    EPS: $-2.50-13.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $4.26M-30.1%
    |
    EPS: $-0.77-5.2%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $4.87M+17.9%
    |
    EPS: $-0.66-8.6%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月13日|
    売上高: $5.05M+22.0%
    |
    EPS: $-0.61-1237.0%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月1日|
    売上高: $22.39M+36.6%
    |
    EPS: $-2.20-136.7%
    予想を下回る